GauchoRico | 2026-02-22
Holy smokes!! Hinge Health delivered one of the cleanest post-IPO earnings reports I've seen in years. Q4 revenue of $170.7m beat guidance by $14.7m (+9.4%) — the third consecutive 12 − 14mbeat.Grossmarginshit8536.6m operating income in Q1 FY23 to $47.8m operating income in Q4 FY25, with 85% gross margins and a genuine AI operating leverage story. The deceleration from 51% to 46% matters — I'll address it — but the underlying business here is exceptional.
| | Q1 FY23 | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | | | Mar-23 | Jun-23 | Sep-23 | Dec-23 | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---|---|---|---|---|---|---|---| | Revenue ($m) | 60.0 | 69.4 | 78.4 | 84.9 | 87.5 | 93.8 | 92.4 | 116.7 | 126.9 | 139.1 | 154.2 | 170.7 | | YoY % | — | — | — | — | 46% | 35% | 18% | 37% | 45% | 48% | 67% | 46% | | QoQ % | — | 16% | 13% | 8% | 3% | 7% | -1% | 26% | 9% | 10% | 11% | 11% | | GM [Non-GAAP] % | 62% | 64% | 67% | 68% | 71% | 73% | 74% | 76% | 80% | 83% | 85% | 85% | | OpM [Non-GAAP] % | -61% | -49% | -37% | -24% | -18% | -12% | -9% | 3% | 9% | 17% | 22% | 28% | | FCF ($m) | — | — | — | — | — | — | 25.0 | 20.2 | 27.9 | 37.0 | 53.1 | 61.5 | | FCF Margin % | — | — | — | — | — | — | 27% | 17% | 22% | 27% | 34% | 36% | | Non-GAAP EPS | — | — | — | — | — | — | — | $0.40 | $0.28 | $0.32 | $0.40 | $0.49 |
PASS — but watching the trajectory
Q4 FY25: 46% YoY. FY25 full year: 51% YoY. Still comfortably above my 40% minimum. The deceleration trend is real: Q1 FY25 45% → Q2 48% → Q3 67% (easy comp) → Q4 46%. The FY26 guide implies 25% — that's a significant step down and my biggest concern here.
However, I need to respect what TTM billings are telling me. TTM calculated billings hit $671.4m (+44% YoY). Revenue in FY25 was $587.9m. That's a 1.14x billings-to-revenue ratio — meaning there is $80+ million of contracted future revenue sitting unrecognized. The guidance of $732-742m for FY26 implies roughly $155m of incremental revenue. TTM billings already imply a $700m+ run rate. Management has beaten guidance by $12-15m three quarters in a row. I would be shocked if 25% is the actual outcome.
My estimate: 30-35% actual growth in FY26 if business continues to execute as it has. That still qualifies.
NEUTRAL — decelerating but billings + new channels diverge
Sequential growth has been steady at 9-11% per quarter for the past three quarters. YoY deceleration from 53% → 46% is a full 7 points. But I need to separate revenue recognition timing from underlying demand:
The revenue trajectory is showing decel. The demand trajectory is not. I'll watch this closely — if Q1 FY26 comes in below $173m (the guide midpoint), that changes things. If they beat by $12m+ again, the thesis strengthens.
STRONG PASS
85% Non-GAAP gross margin is exceptional. It has expanded 23 percentage points over 12 quarters — from 62% to 85%. This is not maintenance, this is structural improvement driven by operating leverage and AI efficiency.
The AI story here is real and quantified: Hinge served 47% more members in FY25 while keeping care team costs flat. Robin AI has a 92% positive rating and higher response rates than human care teams. This is not AI hype — this is margin expansion you can see in the income statement. I expect gross margins to stabilize at 85-87% and for operating leverage to compound from here.
STRONG
This is where Hinge Health gets interesting. Three durable moats:
Clinical data moat: 100M+ lifetime treatment sessions, 21 peer-reviewed studies, 60% fewer imaging visits proven. Sword Health (their main competitor, ~10M lives) has 5-7 studies. The clinical evidence gap is years of work. Employers and health plans making multi-year commitments care deeply about this.
Embedded distribution: 53% of Fortune 100, 45% of Fortune 500, 5/5 top health plans, 3/3 top PBMs, 60+ partners, 100% partner retention. They are woven into the benefits infrastructure. NDR >110% means existing clients expand without incremental sales cost. Client NPS 88 is among the highest in enterprise software.
Hardware + in-person integration: The Enso wearable and Hinge Select provider network (in 100+ metros) creates a physical-digital integration that pure software competitors cannot match. 85% of Hinge Select members adopt conservative care — that's surgical cost avoidance at scale, which is the argument that wins the CFO negotiation.
ATH win rates in Q4 despite 25%+ client adds. No real competitor is taking share.
CHEAP — meaningfully so
At market cap ~$3.3B and TTM revenue of $587.9m:
Peers with similar growth and margin profiles trade at 8-12x revenue, 25-35x FCF. On any comparable metric, HNGE is trading at a 40-50% discount.
Growth-adjusted: EV/Rev ÷ YoY growth = 5.6 ÷ 0.51 = 0.11x. Below 0.5x is compelling. This is exceptional.
Why is it cheap?
None of these are business problems. They are temporary valuation dislocations. CRM went through the same dynamic in its early quarters of public life.
If HNGE delivers 30% growth in FY26 at 85% gross margins and continues FCF margin expansion toward 35%+, a fair multiple is 8-10x forward revenue. On FY26 $737m guide (likely beats to $800m+), that's a $5.9-8.0B market cap — 80-140% upside from current $3.3B.
YES — multiple present
| Metric | Q4 FY23 | Q4 FY24 | Q4 FY25 | YoY |
|---|---|---|---|---|
| Clients | 1,657 | 2,256 | 2,830 | +26% |
| Members | 370,526 | 532,326 | 782,890 | +47% |
| Contracted Lives (M) | — | 20.0 | 24.6 | +24% |
| Avg Eligible Lives (M) | 12.2 | 15.7 | 20.1 | +28% |
| Annual Yield | 3.4% | 3.4% | 3.9% | +50bps |
| First-Year Cohort Yield | — | — | 3.3% | vs 1.3-2.5% hist. |
| LTM Calculated Billings ($m) | 328.8 | 467.5 | 671.4 | +44% |
| NDR | — | — | >110% | First disclosure |
| Client Retention | — | — | 97% | — |
| Partner Retention | — | — | 100% | — |
| Non-ASO Lives (M) | — | ~1.1 | 2.6 | +130% |
The most important number here is Annual Yield moving from 3.4% to 3.9%. This is the revenue per eligible life. First-year cohort yield at 3.3% (vs historical 1.3-2.5%) suggests the newer client cohorts are engaging at higher rates from day one — which means the 24.6M contracted lives will generate more revenue per life than historical precedent implies. That's a quiet beat embedded in future quarters.
CEO Daniel Perez:
CFO James Budge:
President James Pursley:
Prior (no prior Gaucho analysis — first review):
Post-earnings updated view:
| Guide | Actual | Beat $ | Beat % | |
|---|---|---|---|---|
| Q3 FY25 | $142-144m | $154.2m | +$11.2m | +8% |
| Q4 FY25 | $155-157m | $170.7m | +$14.7m | +9.4% |
| FY25 | $572-574m | $587.9m | +$14.9m | +2.6% |
Q1 FY26 guide: $171-173m midpoint. If the 12 − 14mbeatpatternholds → actual 183-185m. FY26 guide: 732 − 742m(737m midpoint). Conservative assumptions: yield flat, ASP flat, Hinge Select excluded, CMS excluded.
The guide cadence is consistent: management is laying a low bar and clearing it comfortably. Three data points is enough to call this a pattern.
| Metric | HNGE | Notes |
|---|---|---|
| Market Cap | ~$3.3B | ~84M diluted shares × ~$39 |
| EV/TTM Revenue | ~5.6x | TTM $587.9m |
| EV/TTM FCF | ~18x | TTM ~$180m |
| Non-GAAP P/E | ~17x | TTM EPS ~$1.49 |
| EV/FY26E Revenue | ~4.5x | On $737m guide |
| Rule of 40 | 81 | FY25 full year |
CRM context: Salesforce maintained 20%+ FCF margins from $110m to $15B in revenue. At similar phase (post-IPO, building distribution), CRM traded at 10-15x revenue. HNGE at 5.6x with 85% GM and 36% FCF margins is a significant discount to that benchmark.
For LEAPS consideration: if HNGE re-rates to 8x forward revenue on $800m of FY26 actual revenue (my estimate), that's $6.4B market cap — roughly 95% upside from current $3.3B. At that level, LEAPS on HNGE would be compelling. I'd look at Jan '27 or Jan '28 calls at a modest premium to current price as the fundamental case plays out.
Growth deceleration is real. Even if guidance is sandbagged, the trajectory from 51% → 25% guide is steep. If execution slips — new client adds slow, yield stays flat — the multiple compression will be punishing at any revenue multiple. This is my top risk.
Single product concentration. >95% MSK. Pelvic floor (Progyny partnership) is early. If MSK penetration ceiling hits before new verticals scale, growth will stall.
Non-ASO economics unproven at scale. 130% growth is exciting but Medicare Advantage has different reimbursement dynamics, longer sales cycles, and uncertain margins. Scaling from 2.6M to 10M+ non-ASO lives is a different kind of growth than employer sales.
Sword Health IPO. Competitor IPO in 2026 could split analyst and investor attention, potentially reprice HNGE or accelerate competitive win-rate tracking.
Insider selling pressure. Post-lockup, some selling expected. $665m buyback is a strong counter but individual executives selling is a sentiment headwind.
HNGE had an exceptional Q4 and FY25. Every financial metric beat guidance substantially. The AI operating leverage story is real and compounding in the margin structure. The valuation is genuinely cheap — ~5.6x TTM revenue for a 50% grower with 85% gross margins is a gift.
The deceleration concern is legitimate and must be monitored. FY26 guide of 25% is my primary thesis risk. But the body of evidence — TTM billings +44%, clients +26%, members +47%, NDR >110%, new channels excluded from guidance, three consecutive $12-14m beats — points overwhelmingly toward that guide being sandbagged.
Action: HOLD with high conviction. Watch for LEAPS opportunity.
Position is currently 7.4% in wsm portfolio. I'd be comfortable adding if the stock dips on any lockup selling or sector weakness. A 10-12% allocation with LEAPS overlay would be appropriate given the valuation disconnect and growth profile.
If Q1 FY26 revenue comes in at $183m+ (my estimate), the market will reprice this significantly. We will see what happens...
GR